Stryker acquires company specializing in meniscal injury treatment

Sprinter beginning run

Stryker’s endoscopy unit has acquired Ivy Sports Medicine. According to the announcement, through this acquisition Stryker will be able to offer a “complete meniscal platform” to customers.

Courtesy of Ivy Sports Medicine
Ivy Sports Medicine’s portfolio includes the only FDA-approved collagen meniscus implant (CMI) on the market. Also included are an all-inside repair device and an inside-out meniscal suturing platform.

The implant is biological and absorbable. It is made of purified collagen and has a porous structure. Once it is arthroscopically attached, the implant fills the open area that results from damaged or lost meniscal tissue. The implant acts as somewhat of a guide for the migration of the body’s natural cells and is completely absorbed after healing.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

Stryker’s portfolio of products that include visualization, resection, fluid management and ACL reconstruction will be complemented by Ivy Sports Medicine’s sole focus on meniscal injuries.

"The acquisition of Ivy Sports Medicine strengthens our capabilities and fits strategically with our current portfolio. Ivy's complete meniscal platform, coupled with their clinical history, will allow us to provide our customers with multiple solutions to address meniscal repair," said Matt Moreau, vice president and general manager of Stryker's Sports Medicine business, in the announcement.  "This is an area of sports medicine where there is continued opportunity to address unmet customer needs. The Ivy portfolio provides a unique platform for us to build upon as we seek to continue advancing the treatment of meniscal injuries."

"Ivy Sports Medicine was formed to capitalize on the unmet opportunity in meniscal repair, which we view as one of the more attractive growth opportunities in all of orthopaedics," said Robert Pangia, CEO of Ivy Sports Medicine, in the announcement. "Our products provide surgeons with a complete set of tools to treat a large spectrum of meniscal repairs. We are excited about the prospects of combining these products with Stryker's distribution channels and complementary portfolio of sports medicine products."

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.